ESPR Overview
Upcoming Projects (ESPR)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ESPR)
-
A Third View: Discussing the recent label expansion of NEXLETOL/NEXLIZET (bempedoic acid).
Ticker: ESPR
Executed On: Apr 02, 2024 at 07:30 PM EDT -
A Second View: Discussing the recent label expansion of NEXLETOL/NEXLIZET (bempedoic acid).
Ticker: ESPR
Executed On: Mar 29, 2024 at 10:00 AM EDT -
Discussing the recent label expansion of NEXLETOL/NEXLIZET (bempedoic acid).
Ticker: ESPR
Executed On: Mar 28, 2024 at 03:30 PM EDT -
A Third look: Discussing the CLEAR Outcomes study presented at the American College of Cardiology Conference in treating patients using NEXLETOL (bempedoic acid).
Ticker: ESPR
Executed On: Mar 19, 2023 at 12:00 PM EDT -
A Second look: Discussing the CLEAR Outcomes study presented at the American College of Cardiology Conference in treating patients using NEXLETOL (bempedoic acid).
Ticker: ESPR
Executed On: Mar 15, 2023 at 05:00 PM EDT -
Discussing the CLEAR Outcomes study presented at the American College of Cardiology Conference in treating patients using NEXLETOL (bempedoic acid).
Ticker: ESPR
Executed On: Mar 14, 2023 at 09:00 AM EDT -
A Third look: Discuss the standard of care and the launch bempedoic acid (NEXLETOL) and the CVOT outcome studies from Esperion in treating patients with atherosclerotic cardiovascular disease (ASCVD).
Ticker: ESPR
Executed On: Oct 13, 2022 at 02:30 PM EDT -
Discuss the standard of care and the launch bempedoic acid (NEXLETOL) and the CVOT outcome studies from Esperion in treating patients with atherosclerotic cardiovascular disease (ASCVD).
Ticker: ESPR
Executed On: Oct 06, 2022 at 09:30 AM EDT
Upcoming & Overdue Catalysts (ESPR)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (ESPR)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
